Roivant Sciences Ltd. Files 8-K
Ticker: ROIV · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1635088
Sentiment: neutral
Topics: sec-filing, financial-reporting
TL;DR
Roivant Sciences filed an 8-K, standard financial update.
AI Summary
Roivant Sciences Ltd. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event.
Why It Matters
This filing signifies Roivant Sciences Ltd. is providing updates on its financial performance and operational status as required by the SEC.
Risk Assessment
Risk Level: low — This is a routine SEC filing for reporting financial and operational information, not indicating any immediate adverse events.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- 0001140361-24-036281 (filing_id) — Accession Number
- August 8, 2024 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing for Roivant Sciences Ltd.?
The primary purpose is to report on Roivant Sciences Ltd.'s results of operations and financial condition.
When was this 8-K filing submitted?
The filing was submitted on August 8, 2024.
What is the exact name of the reporting company?
The exact name of the reporting company is Roivant Sciences Ltd.
What is the Commission File Number for Roivant Sciences Ltd.?
The Commission File Number for Roivant Sciences Ltd. is 001-40782.
Where is Roivant Sciences Ltd. incorporated?
Roivant Sciences Ltd. is incorporated in Bermuda.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-08-08 07:15:53
Key Financial Figures
- $0.0000000341740141 — ge on which registered Common Shares, $0.0000000341740141 par value per share ROIV The Nasdaq
Filing Documents
- ef20033756_8k.htm (8-K) — 33KB
- ef20033756_ex99-1.htm (EX-99.1) — 205KB
- 0001140361-24-036281.txt ( ) — 387KB
- roiv-20240808.xsd (EX-101.SCH) — 4KB
- roiv-20240808_lab.xml (EX-101.LAB) — 21KB
- roiv-20240808_pre.xml (EX-101.PRE) — 16KB
- ef20033756_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 8, 2024, Roivant Sciences Ltd. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this "Item 2.02. Results of Operations and Financial Condition" (including the exhibit thereto) shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Roivant Sciences Ltd. Press Release, dated August 8, 2024 104 Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory Dated: August 8, 2024